PEPGEN INC. - COMMON S

PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy

18 May 2023 06:00:01 By Nasdaq GlobeNewswire

PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments

11 May 2023 06:00:01 By Nasdaq GlobeNewswire

PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference

04 May 2023 07:00:01 By Nasdaq GlobeNewswire

PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting

17 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference

13 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments

23 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference

22 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

PepGen to Participate in the Stifel 2023 CNS Days Conference

21 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call

16 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference

13 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

PepGen to Participate in the SVB Securities Global Biopharma Conference

09 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

07 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates

14 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

10 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

PepGen to Participate in the Stifel 2022 Healthcare Conference

08 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress

13 Oct 2022 12:00:00 By Nasdaq GlobeNewswire

PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

28 Sep 2022 05:00:00 By Nasdaq GlobeNewswire

PepGen Appoints Habib Dable to Board of Directors

22 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

12 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

PepGen Appoints Caroline Godfrey, Ph.D. to the Company’s Scientific Advisory Board

22 Jul 2022 06:45:00 By Nasdaq GlobeNewswire